Page 125 - 《中国药房》2026年8期

1762. [19] LIN Y M，XU H M，YUN J W，et al. The efficacy of vono‐
[ 8 ] SHIH C A，WU D C，SHIE C B，et al. Dual therapies con‐ prazan combined with different dose amoxicillin on eradi‐
taining an antibiotic plus a proton pump inhibitor or vono‐ cation of Helicobacter pylori：an open，multicenter，ran‐
prazan for Helicobacter pylori infection：a systematic domized clinical study[J]. Ann Transl Med，2022，10
review[J]. Microorganisms，2025，13（4）：715. （18）：987.
[ 9 ] STERNE J A C，SAVOVIĆ J，PAGE M J，et al. RoB 2：a [20] LIU Z，SUN D J，KOU L，et al. Vonoprazan-amoxicillin
revised tool for assessing risk of bias in randomised trials dual therapy with different amoxicillin dosages for
[J]. BMJ，2019，366：l4898. treatment-naive patients of Helicobacter pylori infection
[10] 张天嵩. Stata软件network组命令在网状Meta分析中的 in China：a prospective，randomized controlled study[J].
应用[J]. 中国循证医学杂志，2015，15（11）：1352-1356. Eur J Gastroenterol Hepatol，2024，36（6）：712-719.
[11] YAN K F，DAI X R，LI Z X，et al. Clinical study on the [21] 段萌，李佳颖，霍丽娟. 大剂量二联方案与含铋剂四联方
eradication of Helicobacter pylori by vonoprazan com‐ 案根除幽门螺杆菌的疗效观察[J]. 国际消化病杂志，
bined with amoxicillin for 10-day dual therapy[J]. Clin 2023，43（6）：407-411，416.
Pharmacol Drug Dev，2024，13（3）：240-247. [22] 郭钿，林焕雄，庄康敏. 高剂量伏诺拉生联合阿莫西林二
[12] HAN Y Y，ZHOU L，HU Y L，et al. Comparison of 联治疗幽门螺杆菌感染的疗效及安全性[J]. 中国医师杂
vonoprazan-based with rabeprazole-based dual therapy for 志，2024，26（12）：1904-1907.
treatment-naive patients of Helicobacter pylori infection： [23] SALAHI-NIRI A，NABAVI-RAD A，MONAGHAN T M，
a prospective，multi-center，randomized controlled study et al. Global prevalence of Helicobacter pylori antibiotic
[J]. J Gastroenterol，2023，58（12）：1167-1177. resistance among children in the World Health Organiza‐
[13] HU Y，ZHANG Z Y，WANG F，et al. Effects of amoxicil‐ tion regions between 2000 and 2023：a systematic review
lin dosage on cure rate，gut microbiota，and antibiotic re‐ and meta-analysis[J]. BMC Med，2024，22（1）：598.
sistome in vonoprazan and amoxicillin dual therapy for [24] ZHANG J，ZHANG H，ZHU X J，et al. Efficacy and
Helicobacter pylori：a multicentre，open-label，non- safety of vonoprazan and high-dose amoxicillin dual
inferiority randomised controlled trial[J]. Lancet Microbe， therapy in eradicating Helicobacter pylori：a systematic
2025，6（3）：100975. review and meta-analysis[J]. Int J Antimicrob Agents，
[14] PENG X，YAO J Y，MA Y Q，et al. Efficacy and safety of 2024，64（5）：107331.
vonoprazan-amoxicillin dual regimen with varying dose [25] KONG Q Z，JU K P，LI Y Y. Optimizing Helicobacter
and duration for Helicobacter pylori eradication：a multi‐ pylori eradication therapies：from trial to real world[J].
center，prospective，randomized study[J]. Clin Gastroen‐ Clin Gastroenterol Hepatol，2024，22（12）：2542.
terol Hepatol，2024，22（6）：1210-1216. [26] SHIN J M，INATOMI N，MUNSON K，et al. Characteriza‐
[15] PENG R L，CAI P P，ZHANG Z M，et al. Efficacy of tion of a novel potassium-competitive acid blocker of the
three amoxicillin doses in vonoprazan dual therapy for gastric H，K-ATPase，1-[5-（2-fluorophenyl）-1-（pyridin-3-
Helicobacter pylori eradication：a randomized noninferio- ylsulfonyl）-1H-pyrrol-3-yl]-N-methylmethanamine mono‐
rity trial[J]. Helicobacter，2025，30（3）：e70050. fumarate（TAK-438）[J]. J Pharmacol Exp Ther，2011，339
[16] KONG Q Z，MIRZA I A，ZHANG X Q，et al. Fourteen- （2）：412-420.
day tegoprazan-amoxicillin dual therapy as the first-line [27] CHO J H，JIN S Y. Comparison of amoxicillin adminis‐
treatment of Helicobacter pylori infection（SHARE2301）： tered twice versus four times a day in first-line Helicobacter
a multicenter，noninferiority，randomized clinical trial[J]. pylori eradication using tegoprazan，clarithromycin，and
Helicobacter，2024，29（3）：e13098. bismuth：a propensity score matching analysis[J]. Microor‐
[17] TAO L L，QIAN H S，ZHANG L Y，et al. Optimizing du‐ ganisms，2024，12（10）：1952.
ration and dosing frequency of vonoprazan-amoxicillin [28] GRAHAM D Y，SHIOTANI A. New concepts of resis‐
dual therapy for Helicobacter pylori：a multicenter ran‐ tance in the treatment of Helicobacter pylori infections[J].
domized trial[J]. Helicobacter，2025，30（4）：e70062. Nat Clin Pract Gastroenterol Hepatol，2008，5（6）：321-331.
[18] ZHOU B G，GUO M W，ZHANG L J，et al. Ten-day vono- [29] DING Y M，DUAN M，HAN Z X，et al. Bismuth-
prazan-amoxicillin dual therapy versus 14-day esomeprazole- containing quadruple therapy for Helicobacter pylori
amoxicillin dual therapy for first-line Helicobacter pylori eradication：a randomized clinical trial of 10 and 14 days
eradication：a prospective multicenter randomized con‐ [J]. Dig Dis Sci，2024，69（7）：2540-2547.
trolled trial[J]. Therap Adv Gastroenterol，2024，17： （收稿日期：2025-12-24 修回日期：2026-04-03）
17562848241309870. （编辑：陈 宏）

中国药房 2026年第37卷第8期 China Pharmacy 2026 Vol. 37 No. 8 · 1079 ·